top of page
Search

Worldwide Cancer Research Grant for MAASTRO on eradicating hypoxia in esophageal cancer

  • Writer: Marc Vooijs
    Marc Vooijs
  • Nov 11, 2014
  • 1 min read

A Worldwide cancer research grant has been obtained to study the efficacy of the hypoxia-activated bioreductive prodrug TH-302 in combination with radiotherapy on esophageal tumors. We will investigate the therapeutic impact of TH-302 on radiotherapy using a panel of human esophageal tumor models, to prove that TH-302 efficacy is dependent on the tumor oxygenation status and we will evaluate the value of non-invasive hypoxia PET imaging to predict TH-302 treatment efficacy. Additionally, the possible short-term and long-term normal tissue toxicity of TH-302 and high-dose irradiation with or without oxygen modification using respectively esophagitis and lung pneumonitis/fibrosis assays will be assessed. We are looking for a junior PostDoc to join our team.

Recent Posts

See All

Comments


Featured Posts
Recent Posts
Archive
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

Copyright © 2023 | Maastricht Radiation Oncology Lab Maastricht University / MUMC

  • Google Places Social Icon
  • Facebook Social Icon
  • Twitter Social Icon
bottom of page